NMS Labs
3701 Welsh Road, PO Box 433A, Willow Grove, PA 19090-0437
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 08/07/2018 12:19
Last Report Issued 12/12/2017 11:22

88888
Clinical Example Report
Attn: IT Department
3701 Welsh Road
Willow Grove, PA 19090

Patient Name 9248SP-POS
Patient ID 9248SP-POS
Chain 17002291
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 17002291

Received 12/12/2017 08:05

Sample ID 17002291-001
Matrix Serum or Plasma
Patient Name 9248SP-POS
Patient ID 9248SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
9248SP Pseudoephedrine Screen, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Pseudoephedrine	See Comment	ng/mL	5.0	
Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).				
5568SP Pseudoephedrine Confirmation, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Pseudoephedrine	50	ng/mL	5.0	

Results for sample 17002291-001 are continued on next page

NMS Labs
3701 Welsh Road, PO Box 433A, Willow Grove, PA 19090-0437
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 17002291-001
Matrix Serum or Plasma
Patient Name 9248SP-POS
Patient ID 9248SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Following a 60 mg oral dose (immediate-release tablet or syrup), mean peak plasma concentrations of 180 to 360 ng/mL were reported at 3 hours.				
Following a 120 mg oral dose (controlled-release capsule), mean peak plasma concentrations of 265 to 315 ng/mL were reported.				
Chronic administration of 360 mg/day (of a controlled-release preparation) resulted in mean steady-state plasma concentrations between 500 and 640 ng/mL over a 10-day period.				